Taken together with the EMPA-REG OUTCOME trial, previous clinical studies showed benefits of SGLT-2 inhibitors on cardiac function in patients with type 2 diabetes, ischemic heart and heart failure [28–33]. Here, SLC5A2 is linked to type 2 diabetes mellitus.